104 related articles for article (PubMed ID: 7546903)
1. Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope.
Lee CN; Robinson J; Mazzara G; Cheng YL; Essex M; Lee TH
AIDS Res Hum Retroviruses; 1995 Jul; 11(7):777-81. PubMed ID: 7546903
[TBL] [Abstract][Full Text] [Related]
2. Influence of deletions in N or C terminus of HIV-1 glycoprotein 120 on binding of infectivity-enhancing antibody.
Lee CN; Robinson J; Cheng YL; Essex M; Lee TH
AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1065-9. PubMed ID: 7530023
[TBL] [Abstract][Full Text] [Related]
3. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
[TBL] [Abstract][Full Text] [Related]
4. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
5. Neutralization epitopes of the HIV-1 primary isolate DH012.
Zhu C; Matthews TJ; Chen CH
Vaccine; 2003 Jul; 21(23):3301-6. PubMed ID: 12804861
[TBL] [Abstract][Full Text] [Related]
6. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
7. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
9. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
[TBL] [Abstract][Full Text] [Related]
10. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
11. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
[TBL] [Abstract][Full Text] [Related]
12. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A; Honnen WJ; Racho ME; Tilley SA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
[TBL] [Abstract][Full Text] [Related]
13. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
[TBL] [Abstract][Full Text] [Related]
14. The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.
Zhu CB; Zhu L; Holz-Smith S; Matthews TJ; Chen CH
Proc Natl Acad Sci U S A; 2001 Dec; 98(26):15227-32. PubMed ID: 11734627
[TBL] [Abstract][Full Text] [Related]
15. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
Kim YB; Han DP; Cao C; Cho MW
Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
[TBL] [Abstract][Full Text] [Related]
17. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
Moore JP; McCutchan FE; Poon SW; Mascola J; Liu J; Cao Y; Ho DD
J Virol; 1994 Dec; 68(12):8350-64. PubMed ID: 7525988
[TBL] [Abstract][Full Text] [Related]
18. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
19. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
Wyatt R; Sullivan N; Thali M; Repke H; Ho D; Robinson J; Posner M; Sodroski J
J Virol; 1993 Aug; 67(8):4557-65. PubMed ID: 8331723
[TBL] [Abstract][Full Text] [Related]
20. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
